bioMérieux: Invest Securities reiterates 'sell' rating

(CercleFinance.com) - Invest Securities reiterates its "sell" rating on bioMérieux, while nudging up its target price for the share from 55 euros to 56 euros, after the share price's 5.
2% fall after publishing results that are line with expectations in organic terms.

It explains this reaction with a disappointment on FX factors, but also the market's caution given the few existing levers in 2018 (zero growth in EBITA in 2018, end of influenza epidemic) and the stock's high valuation.

In organic terms, performance remains robust - especially for molecular biology - even though the comparison basis in terms of the influenza epidemic was very favourable, the analyst tempers, who has revised his FX estimates, although has raised his forecast for the organic growth of BioFire.


Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.